Skip to main
TWST

TWST Stock Forecast & Price Target

TWST Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 33%
Buy 56%
Hold 11%
Sell 0%
Strong Sell 0%

Bulls say

Twist Bioscience is uniquely positioned at the forefront of the growing synthetic biology industry, with its proprietary silicon-based DNA synthesis platform allowing for faster, more affordable and scalable production of high-quality synthetic DNA. The company's strong partnerships and growing demand for AI-driven drug discovery further reinforce its position and potential for continued growth. The company's current focus on cost-efficiency and strategic expansion of its operations provide a clear path for long-term profitability, making it an attractive investment opportunity for investors looking for exposure to the rapidly advancing field of synthetic biology.

Bears say

Twist Bioscience is currently seeing a boost in demand for its products and services due to increasing utilization of artificial intelligence (AI) in biotech and pharma research and development. This has led to strong order growth, which is expected to continue for the foreseeable future. However, there are risks of potential slowdowns in the company's core business and any shortcomings in meeting investor expectations could lead to a decline in the valuation multiple. Additionally, while the recent stock performance has been strong, high expectations could put pressure on the company to deliver strong results in order to maintain investor confidence.

TWST has been analyzed by 9 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 56% recommend Buy, 11% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Twist Bioscience Corp and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Twist Bioscience Corp (TWST) Forecast

Analysts have given TWST a Buy based on their latest research and market trends.

According to 9 analysts, TWST has a Buy consensus rating as of Jul 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $86, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $86, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Twist Bioscience Corp (TWST)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.